Argenta announced that Paul Fry will join the company as its new CFO, starting immediately. To ensure a smooth transition, Paul will work closely with former CFO Chris O’Donnell until late August. The CFO role is being relocated from New Zealand to London to enable the CEO and CFO to work closely together in the same time zone, and to be closer to customers.
Chris O’Donnell, who has served as Argenta’s Chief Financial Officer since 2018, is supportive of the decision and has decided to stay in New Zealand until further notice. He stepped down from his role on June 24 and will stay on until August 26 to support with the transition. Chris has played a leading role in the success and growth of Argenta, providing skilful oversight to key projects including the transition of ownership to KKR and the acquisition of Klifovet.
What were the executive’s thoughts on the appointment?
Will Downie, CEO of Argenta, said: “I am delighted to welcome Paul to Argenta. His proven track record and extensive experience, combined with his strategic financial expertise and outstanding leadership qualities, will have a significant impact on the company. I am excited to partner with Paul to help drive long-term growth and scale for the organization.”
“I would also like to take this opportunity to express my gratitude to Chris O’Donnell for his commitment, partnership, and financial stewardship in the time we have worked together. Chris has helped to lay the solid foundation that supports the company’s ambitious strategy.”
What is the industry expertise of Paul Fry?
Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications. Prior to joining Argenta, he was Chief Financial Officer (CFO) of Vectura Group plc, an industry-leading inhaled drug delivery specialist which was listed on the main market of the London Stock Exchange until 2021. In his time with the company, he played an instrumental role in almost doubling its market valuation.
Before Vectura, Paul was CFO of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor (TCR) tech. He also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GSK, where he held several senior leadership roles.
Paul Fry said: “It is an exciting time to enter the animal health industry and I am delighted to be joining Argenta. The firm has a unique offering, strong track record and the potential for big growth for many years to come. I feel privileged to be able to contribute to this and to have the opportunity to serve Argenta’s customers, team members and shareholders.”
Paul holds a degree from Oxford University and a member of the Chartered Institute of Management Accounts. He is a Non-executive Director and Chair of the Audit Committee at Avacta plc, an AIM-listed biotech company developing diagnostics and oncology therapies.
